Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010

@article{Waters2012UseOT,
  title={Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010},
  author={Erika A Waters and Timothy S. McNeel and Worta McCaskill Stevens and Andrew Nathan Freedman},
  journal={Breast Cancer Research and Treatment},
  year={2012},
  volume={134},
  pages={875-880}
}
Two selective estrogen receptor modulators, tamoxifen and raloxifene, have been shown in randomized clinical trials to reduce the risk of developing primary invasive breast cancer in high-risk women. In 1998, the U.S. Food and Drug Administration (FDA) used these studies as a basis for approving tamoxifen for primary breast chemoprevention in both premenopausal and postmenopausal women at high risk. In 2007, the FDA approved raloxifene for primary breast cancer chemoprevention for… CONTINUE READING
46 Citations
37 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Similar Papers

Loading similar papers…